Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 13/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406965 | 0.80 | HCRTR2 (0.47) | HCRTR2HCRTR1CAPN1KMT2AEGLN1 | |
| SCHEMBL16544035 | 0.79 | HCRTR2 (0.49) | HCRTR2HCRTR1CAPN1KMT2AMYC | |
| SCHEMBL29551359 | 0.78 | MYC (0.57) | HCRTR2HCRTR1CAPN1KMT2AMYC | |
| SCHEMBL7090852 | 0.78 | MYC (0.57) | HCRTR2HCRTR1CAPN1KMT2AMYC | |
| SCHEMBL19585461 | 0.77 | F2RL1 (0.40) | HCRTR2HCRTR1KMT2AEGLN1 | |
| SCHEMBL5663804 | 0.76 | CAPN1 (0.55) | HCRTR2HCRTR1CAPN1MYCLMNA | |
| SCHEMBL29551168 | 0.76 | CAPN1 (0.55) | HCRTR2HCRTR1CAPN1MYCLMNA | |
| SCHEMBL19564476 | 0.75 | CAPN1 (0.49) | HCRTR2HCRTR1CAPN1KMT2AMYC | |
| SCHEMBL14232737 | 0.75 | HCRTR2 (0.52) | HCRTR2HCRTR1CAPN1KMT2AMYC | |
| SCHEMBL29551344 | 0.75 | HCRTR2 (0.46) | HCRTR2HCRTR1CAPN1MYCLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | HIF1AN, EGLN3, EGLN2 | HCRTR2 3311/4885HCRTR1 3181/4885CAPN1 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.